Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information; Extension of Comment Period, 37101 [2020-13278]

Download as PDF Federal Register / Vol. 85, No. 119 / Friday, June 19, 2020 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES [Docket No. CDC–2020–0046; NIOSH–233– C] Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information; Extension of Comment Period Centers for Disease Control and Prevention, HHS. ACTION: Extension of comment period. AGENCY: On May 1, 2020, the National Institute for Occupational Safety and Health (NIOSH), within the Center for Disease Control and Prevention (CDC), opened a docket to obtain public input on the following draft documents: (1) NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings (Procedures); (2) NIOSH List of Hazardous Drugs in Healthcare Settings, 2020 (List), and (3) Managing Hazardous Drug Exposures: Information for Healthcare Settings. Comments were to be received by June 30, 2020. NIOSH is extending the comment period to close on July 30, 2020, to allow stakeholders and other interested parties additional time to respond. SUMMARY: The comment period for the document published on May 1, 2020 (85 FR 25439), is extended. Comments must be received by July 30, 2020. ADDRESSES: You may submit written comments, identified by docket numbers CDC–2020–0046 and NIOSH– 233–C, by either of the following two methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998. Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2020–0046; NIOSH–233–C]. All relevant comments received will be posted without change to https:// www.regulations.gov, including any personal information provided. FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C26, Cincinnati, OH 45226; phone: (513) 533–8132 (not a khammond on DSKJM1Z7X2PROD with NOTICES DATES: VerDate Sep<11>2014 17:17 Jun 18, 2020 Jkt 250001 toll-free number); email: bmackenzie@ cdc.gov. • Monday–Tuesday, December 7–8, 2020, from 9:00 a.m. to 5:00 p.m. ET NIOSH published a notice and request for comment in the Federal Register on May 1, 2020 (85 FR 25439) regarding the development of the NIOSH List of Hazardous Drugs in Healthcare Settings and related risk management information for healthcare settings. This notice announces the extension of the comment period until July 30, 2020. Please note that times are subject to change. If the times change, registrants will be notified directly via email. John J. Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. ADDRESSES: SUPPLEMENTARY INFORMATION: Centers for Disease Control and Prevention 37101 [FR Doc. 2020–13278 Filed 6–18–20; 8:45 am] BILLING CODE 4163–18–P Meetings Announcement for the Physician-Focused Payment Model Technical Advisory Committee Required by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); Correction Notice of public meetings; correction. ACTION: The Department of Health and Human Services published a document in the Federal Register of November 29, 2019 detailing the 2020 PTAC meeting dates and the link that connects to the meeting registration website. The March meeting date was postponed until June due to the public health emergency. The June meeting date has been shortened to a one day meeting that will be taking place from 10:00 a.m. to 3:00 p.m. ET virtually. FOR FURTHER INFORMATION CONTACT: Audrey McDowell, Designated Federal Official, at the Office of Health Policy, Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, 200 Independence Ave. SW, Washington, DC 20201, (202) 690–6870. SUPPLEMENTARY INFORMATION: SUMMARY: Correction In the Federal Register of November 29, 2019, in FR Doc. 2019–25898, on page 65828, in the first column, correct the ‘‘DATES’’ caption to read: DATES: The 2020 PTAC meetings will occur on the following dates: • Monday, June 22, 2020, from 10:00 a.m. to 3:00 p.m. ET • Tuesday–Wednesday, September 15– 16, 2020, from 9:00 a.m. to 5:00 p.m. ET Frm 00042 Fmt 4703 In the Federal Register of November 29, 2019, in FR Doc. 2019–25898, on page 65828, in the first column, correct the ‘‘ADDRESS’’ caption to read: All 2020 PTAC meetings will be held in the Great Hall of the Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201 or virtually. Correction DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Correction Sfmt 4703 In the Federal Register of November 29, 2019, in FR Doc. 2019–25898, on page 65828, in the first column, correct the FOR FURTHER INFORMATION CONTACT caption to read: FOR FURTHER INFORMATION CONTACT: Audrey McDowell, Designated Federal Officer, (202) 690–6870. Correction In the Federal Register of November 29, 2019, in FR Doc. 2019–25898, on page 65828, beginning in the first column and continuing to the second column, correct the ‘‘Meeting Attendance’’ caption to read: Meeting Attendance. These meetings are open to the public. For meetings that are held in the Great Hall of the Hubert Humphrey Building, the public may attend in person, via conference call, or view the meeting via livestream at www.hhs.gov/live. The conference call dial-in information will be sent to registrants prior to the meeting. Space may be limited, and registration is preferred. For meetings that are held virtually, the public may by attend via virtual meeting WebEx link (including a dial-in only option), or view the meeting via livestream at www.hhs.gov/live. Registration may be completed online at https://www.cvent.com/d/gbq2tg. Name, organization name, and email address are submitted when registering. Registrants will receive a confirmation email shortly after completing the registration process. Dated: June 10, 2020. Brenda Destro, Deputy Assistant Secretary for Planning and Evaluation (HSP). [FR Doc. 2020–13186 Filed 6–16–20; 4:15 pm] BILLING CODE 4150–15–P E:\FR\FM\19JNN1.SGM 19JNN1

Agencies

[Federal Register Volume 85, Number 119 (Friday, June 19, 2020)]
[Notices]
[Page 37101]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13278]



[[Page 37101]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2020-0046; NIOSH-233-C]


Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in 
Healthcare Settings, 2020; Procedures; and Risk Management Information; 
Extension of Comment Period

AGENCY: Centers for Disease Control and Prevention, HHS.

ACTION: Extension of comment period.

-----------------------------------------------------------------------

SUMMARY: On May 1, 2020, the National Institute for Occupational Safety 
and Health (NIOSH), within the Center for Disease Control and 
Prevention (CDC), opened a docket to obtain public input on the 
following draft documents: (1) NIOSH Procedures for Developing the 
NIOSH List of Hazardous Drugs in Healthcare Settings (Procedures); (2) 
NIOSH List of Hazardous Drugs in Healthcare Settings, 2020 (List), and 
(3) Managing Hazardous Drug Exposures: Information for Healthcare 
Settings. Comments were to be received by June 30, 2020. NIOSH is 
extending the comment period to close on July 30, 2020, to allow 
stakeholders and other interested parties additional time to respond.

DATES: The comment period for the document published on May 1, 2020 (85 
FR 25439), is extended. Comments must be received by July 30, 2020.

ADDRESSES: You may submit written comments, identified by docket 
numbers CDC-2020-0046 and NIOSH-233-C, by either of the following two 
methods:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: National Institute for Occupational Safety and 
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, 
Ohio 45226-1998.
    Instructions: All information received in response to this notice 
must include the agency name and docket number [CDC-2020-0046; NIOSH-
233-C]. All relevant comments received will be posted without change to 
https://www.regulations.gov, including any personal information 
provided.

FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A. 
Taft Laboratories, 1090 Tusculum Avenue, MS-C26, Cincinnati, OH 45226; 
phone: (513) 533-8132 (not a toll-free number); email: 
[email protected].

SUPPLEMENTARY INFORMATION: NIOSH published a notice and request for 
comment in the Federal Register on May 1, 2020 (85 FR 25439) regarding 
the development of the NIOSH List of Hazardous Drugs in Healthcare 
Settings and related risk management information for healthcare 
settings. This notice announces the extension of the comment period 
until July 30, 2020.

John J. Howard,
Director, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2020-13278 Filed 6-18-20; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.